Should You Invest in Novo Nordisk (NVO) Ahead of Q1 Earnings?

Danish pharma goliath, Novo Nordisk (NVO) , is slated to report first-quarter 2024 results on May 2, before the opening bell.The Zacks Consensus Estimate for the company’s first-quarter revenues is pegged at $9.23 billion, while the same for earnings is pinned at 77 cents per share, both indicating significant increases from the year-ago quarter.Revenue growth in the first quarter of 2024 is expected to have been driven by strong demand for Novo Nordisk’s diabetes and obesity care medicines, especially sema ...